重组人生长激素对特发性矮小症患者的内分泌轴GHRH/GH/IGF-1的影响  

Effects of recombinant human growth hormone on the endocrine axis GH-RH/GH/IGF-1 in patients with idiopathic short stature

作　　者：张明英 钱莹 高龙[1] 边乐 吴楠景 吕玲[1] ZHANG Ming-ying;QIAN Ying;GAO Long;BIAN Le;WU Nan-jing;Lü Ling(Department of Pediatrics,Tianjin Children’s Hospital,Tianjin 300134,China)

机构地区：[1]天津市儿童医院儿科,天津300134

出　　处：《哈尔滨医科大学学报》2022年第1期47-50,共4页Journal of Harbin Medical University

基　　金：天津市自然科学基金资助项目(16JCQNJC11900)。

摘　　要：目的 研究重组人生长激素(recombinant human growth hormone, rhGH)对特发性矮小症(idiopathic short stature, ISS)患者的内分泌轴GHRH/GH/IGF-1的影响。方法 选取2019年2月~2021年2月于本院治疗的ISS患者86例,在患者睡前一次性给予0.15 U/kg的rhGH,持续治疗24个月。期间通过X射线骨龄测定仪、酶联免疫吸附剂测定法(enzyme linked immunosorbent assay, ELISA)和实时荧光定量PCR(quantitative real-time PCR,qPCR)检测并记录接受治疗不同时期的身高、体重、骨龄、垂体功能、生长激素释放激素(growth hormone releasing hormone, GHRH)、胰岛素样生长因子1(insulin-like growth factor 1,IGF-1)和生长激素受体(growth hormone receptor, GHR)基因水平变化情况。结果 随着治疗时间加长,患儿的身高、体重、生长速率与IGF-1、GHRH水平均逐渐上升,差异具有统计学意义(P<0.05);除此之外,随着治疗时间增加,患儿垂体功能评分也逐渐升高,差异具有统计学意义(P<0.05)。治疗期间骨龄无明显变化。结论 rhGH能有效促进ISS患儿身高、体重的增长,rhGH可有效提高ISS患儿的内分泌轴GHRH/GH/IGF-1的功能。Objective To study the effect of recombinant human growth hormone(rhGH)on the endocrine axis GHRH/GH/IGF-1 of patients with idiopathic short stature(ISS).Methods Eight six cases with ISS who were treated in our hospital from February 2019 to February 2021 were selected.The patients were given rhGH at a dose of 0.15 U/kg before going to bed for 24 months.During the period,the height,weight,bone age,pituitary function,growth hormone releasing hormone(GHRH),insulin-like growth factor 1(IGF-1)and growth hormone receptor(GHR)gene level changes at different periods of the treatment were detected and recorded by X-ray bone age analyzer,enzyme-linked immunosorbent assay(ELISA)and real-time fluorescent quantitative PCR(qPCR).Results As the treatment time increased,the children1 s height,weight,growth rate and IGF-1 and GHRH levels gradually increased,and the difference was statistically significant(P<0.05);In addition,as the treatment time increases,the pituitary function score of the children also gradually increased,and the difference was statistically significant(P<0.05).There was no significant change in bone age during treatment.Conclusion rhGH can effectively promote the height and weight of children with ISS,and rhGH can effectively improve the function of the endocrine axis GHRH/GH/IGF-1 in children with ISS.

关 键 词：重组人生长激素 特发性矮小症 GHRH/GH/IGF-1 内分泌 

分 类 号：R725.8[医药卫生—儿科]